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Background: Previous studies demonstrated dysregulated expression of microRNAs (miRNAs)
in the myocardium of patients with dilated cardiomyopathy (DCM). This study investigated
levels of miRNAs in the circulation of DCM patients, and the value of miRNAs as biomarkers
for DCM.
Methods and materials: In 45 DCM patients and 39 age- and sex-matched controls, circulating
miR-423-5p, miR-126, miR-361-5p, miR-155, and miR-146a concentrations were measured
and correlated to cardiac functional parameters, including left ventricular ejection fraction
(LVEF) and N-terminal pro-brain natriuretic peptide (NT-proBNP).
Results: Plasma levels of miR-126 and miR-361-5P did not differ between the DCM and
control groups (p ¼ 0.331 and p ¼ 0.784, respectively). Plasma levels of the immunity-
associated miRNAs, miR-146a and miR-155, did not differ between the DCM and control
groups (p ¼ 0.437 and p ¼ 0.702, respectively). Levels of circulating miR-423-5p were
significantly greater in the DCM group (p ¼ 0.003). Further, there was a positive correlation
between plasma levels of miR-423-5p and NT-proBNP (r ¼ 0.430, p ¼ 0.003). MiR-423-5p
distinguished DCM cases from controls with an area under the curve (AUC) receiver
operating characteristic (ROC) curve of 0.674 (95% CI, 0.555e0.793).
Conclusions: Patients with DCM have elevated plasma miR-423-5p levels. The plasma
concentration of miR-423-5p was positively correlated with the level of NT-proBNP.
Circulating levels of miR-423-5p could be served as a diagnostic biomarker for heart
failure caused by DCM. Plasma levels of immunity-associated miR-146a, -155, and -126
were not significantly different between DCM and control groups.
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with disease, thereby suggesting that miRNAs, might be
valuable diagnostic biomarkers.2
Previous reports demonstrated a potential pathophysio-
logical link between expression of miRNAs (miR-126, miR-155,
miR-146a) and immune response for humans with dilated
cardiomyopathy (DCM).3,4 Other studies showed up-regulated
expression of miR-423-5p and miR-361-5p in DCM myocar-
dium.5 The purpose of this study was to characterize levels of
cardiac-associated miRNAs in the circulation of DCM patients
and to determine their value as biomarkers for DCM.2. Materials and methods
2.1. Participants
We recruited 45 DCM patients with New York Heart Associa-
tion (NYHA) function classes IeIV, and a control group of 39
healthy age- and gender-matched volunteers, at the First
Affiliated Hospital (Nanjing Medical University) after obtain-
ing their written informed consent. Inclusion criteria for the
DCM groupwere: a left ventricular ejection fraction (LVEF) less
than 45%, as determined by two-dimensional and Doppler
echocardiography (GE Vivid VII scanner with 1.7e3.4 MHz
transducers); Exclusion criteria were: coronary heart disease
(stenosis >50% of the luminal diameter in a major branch), as
judged by coronary angiography; arterial hypertension (>160/
100 mmHg); primary valvular heart disease; cardiomyopathy
secondary to any systematic disease; clinical, sustained and
rapid supraventricular arrhythmias; pericardial diseases;
congenital heart diseases; cor pulmonale.6 Inclusion criteria
for the control group were: absence of known coronary,
valvular, or myocardial disease. Exclusion criteria for all
participants were: pregnancy, dialysis, and known or treated
malignancies. The Institutional Review Board of the First
Affiliated Hospital approved the study protocol.2.2. N-terminal pro-brain natriuretic peptide (NT-
proBNP) measurements
NT-proBNP was measured using an electro-
chemiluminescence immunoassay (E170 Roche Diagnostics,
Mannheim, Germany).2.3. Plasma RNA purification
Blood samples were collected in tubes containing EDTA (Gong
Dong EDTA K2), and plasma was isolated by centrifugation at
1500 g for 15 min at 4 C. Total RNA was isolated from 400 mL
of plasma using the mirVana PARIS kit (AM1556, Ambion)
according to the manufacturer’s instructions. Before RNA
isolation, 25 fmol of synthetic Caenorhabditis elegans
MicroRNA-39 (cel-miRNA-39; Qiagen, Germany) was added to
the mixture as an internal reference.7 RNA isolated from
plasma was subsequently re-suspended in 100 mL of RNase-
free water, and then stored at 80 C.2.4. Quantitative reverse transcription polymerase
chain reaction (qRT-PCR)
Reverse transcription of miRNAs was performed using the
TaqMan MicroRNA Reverse Kit (Applied Biosystems, Foster,
CA) according to the manufacturer’s recommendations. The
15 mL RT reaction system contained 5 mL of RNA extract, 0.15 mL
of 100 mM dNTPs (with dTTP), 1 mL of multiscribe reverse
transcriptase (50 U/mL), 1.5 mL of 10  RT buffer, 0.19 mL of
RNase inhibitor (20 U/mL), 4.16 mL of RNase-free water, and 3 mL
of 5  miRNA-specific stem-loop RT primer (Applied Bio-
systems, Foster, CA). For real-time quantitative PCR (qRT-
PCR), 1.33 mL of the cDNA product was used as a template in
20 mL reactions containing 1 mL of TaqMan MicroRNA Assay,
7.67 mL of RNase-free water, and 10 mL of TaqMan 2
Universal PCR Master Mix, No AmpErase UNG (Applied Bio-
systems, Foster, CA). qRT-PCR was performed with 7900HT
real-time PCR system (Applied Biosystems, Foster, CA). Trip-
licate measurements were obtained for each sample on a 384-
well plate (Applied Biosystems, Foster, CA). This reaction
contained a miRNA-specific forward primer, and a TaqMan
probe complementary to the 30-end of the specific miNA
sequence. Data were analyzed with SDS Relative Quantifica-
tion Software version 2.2.2 (Applied Biosystems, Foster, CA),
with the automatic Ct setting for assigning baseline and
threshold for Ct determination. The relative expression level
of each individual miRNA after normalization to cel-miRNA-
39 was calculated using the 2
OOCt method.8
2.5. Statistical analyses
Continuous data are presented as mean  standard deviation
(SD). Categorical data are presented as counts and propor-
tions. Values were log-transformed when appropriate for
statistical analysis. Between group comparisons were exam-
ined using unpaired Student’s t-tests and c2 tests for contin-
uous and categorical variables, respectively. One-way ANOVA
was used if more than two groups were compared. For
correlation, Pearson’s or Spearman’s correlation coefficient
was calculated for continuous and categorical data, respec-
tively. Receiver Operating Characteristic (ROC) curve analysis
was used to assess the diagnostic accuracy of miRNAs. The
area under the ROC curve (AUC) was used as diagnostic index.
Statistical significance was assumed at p < 0.05 and was two-
sided. For all statistical analyses, the statistical software SPSS
17.0 (Statistical Package for the Social Sciences, Chicago, IL) for
Windows was used.3. Results
No significant differences in the clinical characteristics of the
study populations were observed (Table 1). NT-proBNP
measurements were only performed on DCM patients, most
of whom were receiving diuretics, angiotensin-converting
enzyme inhibitors, or angiotensin receptor blockers and
b blockers. Plasma levels of miR-126 and miR-361-5P did not
differ between the DCM and control groups (3.59 vs. 3.21,
p¼ 0.331; 5.81 vs. 5.63; p¼ 0.784, respectively). Plasma levels of
the immunity-associated miRNAs, miR-146a andmiR-155, did
Table 1 e Baseline clinical and echocardiographic
characteristics of dilated cardiomyopathy (DCM) patients
and healthy controls. Values are mean ± SD or number
(%).
Characteristic Control DCM p-value
Age (years)a 47.59  11.85 47.76  12.28 0.95
Gender (male) 25(64.1%) 32 (71.1%) 0.64
Ejection fraction (%)a 61.78  4.15 33.80  6.63 <0.01
Creatine (mmol/L)a 73.67  14.75 96.05  30.68 <0.01
NT-proBNP (ng/L)b e 2733.50 (61e35,000)
b-Blockers e 42 (93.3%)
ACEI/ARB e 41 (91.1%)
Diuretics e 41 (91.1%)
NYHA grade e
Class I 2 (4.4%)
Class II 21 (46.7%)
Class III 14 (31.1%)
Class IV 8 (17.8%)
Abbreviations: DCM, dilated cardiomyopathy; NT-proBNP,
N-terminal pro-brain natriuretic peptide; ACEI, angiotensin-
converting enzyme inhibitor; ARB, angiotensin receptor blockers;
NYHA, New York Heart Association.
a Mean þ SD.
b Median (interquartile range).
Fig. 1 e Circulating miRNAs in research cohorts. Expression of
(n [ 45) and control subjects (n [ 39), as determined by TaqMa
Abbreviations: DCM: dilated cardiomyopathy. *Significant differ
levels of miR-146a, -155, -126 and -361-5p were not significant
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p¼ 0.437; 4.13 vs. 4.27, p¼ 0.702, respectively). miR-423-5pwas
the only microRNA that was significantly greater in DCM
patients, compared with controls (5.851 vs. 4.619, p ¼ 0.003)
(Fig. 1). Plasma concentrations of miR-423-5p were positively
correlated with NT-proBNP for the DCM group (Fig. 2 r ¼ 0.430,
p ¼ 0.003). Plasma concentrations of miR-423-5p did not
correlate with NYHA functional class or LVEF values. The
diagnostic accuracy of miR-423-5p was evaluated using ROC
curve analyses with an AUC of 0.674 (Fig. 3 95% confidence
interval 0.555e0.793). By using a thresholdmiR-423-5PLnRQ of
4.017 as the lower limit for patients with DCM, there was
a sensitivity of 87% and a specificity of 49% for patients with
DCM patients.4. Discussion
Previous reports demonstrated a potential pathophysiologic
link between expression of miRNAs (miR-126, miR-155, miR-
146a) and immune response in human DCM.3,4 It was also
demonstrated that circulating levels of some miRNAs were
indices of patients with HF,9,10 although there was limitedmiRNAs in plasma was obtained from patients with DCM
n qRT-PCR. Values were normalized to cel-miR-39.
ences between DCM and control groups (p< 0.01). Plasma
ly different between DCM and control groups.
Fig. 2 e Positive correlation between NT-proBNP and miR-
423-5P in patients with dilated cardiomyopathy (DCM). A
significant relationship was observed (r[ 0.430; p[ 0.003;
n [ 45).
Fig. 3 e Diagnostic accuracy of miRNA-423-5p. A
receivereoperator characteristic (ROC) curve was
established to determine the diagnostic power for
distinguishing DCM cases from healthy people. The area
under the curve (AUC) was 0.674 (95% confidence interval
0.555e0.793). Use of a miR-423-5pLnRQ threshold of 4.017
as the lower limit for patients in the DCM group, resulted in
a sensitivity of 87% and a specificity of 49% for the
identification of DCM patients.
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dysregulation of miR-126 and miR-361-5P plasma levels in
DCM patients, in contrast to reports of patients with ischemic
heart disease by Fukushima and Chen.11,12 This difference
may be explained, in part, by decreased expression of miR-126
in diabetes mellitus and coronary heart disease.13,14 In addi-
tion, elevated expression of miR-361-5p is associated with
metastatic colorectal cancer,15 whereas its involvement in
heart failure is undetermined.
Thomas Thum’s study demonstrated up-regulated
expression of miR-423-5p in DCM myocardium.5 In addition,
Tijsen et al. found that miR-423-5p was able to distinguish
heart failure from healthy controls and patients with dyspnea
attributable to other causes (with an area under the curve of
0.91).9 Similarly, Yaron Goren reported that plasma levels of
miR-423-5p were higher in HF patients than in controls.10
A possible mechanism for this is that expression of miR-423-
5P in cell is up-regulated by ANP.16 We also found that miR-
423-5p mean plasma levels were significantly higher in DCM
patients than in healthy subjects, but the degree of increase
and diagnostic value are conspicuously lower than for the
previous studies. This may be because the previous studies
included ischemic heart disease. This is supported by Tutar-
el’s data, that patients with reduced systemic right ventricle
ejection fraction miR-423-5p levels were not elevated.17
Consequently, microRNA levels associated with different
categories of heart failuremay vary. Therefore, further studies
are needed to evaluate the diagnostic value of miR-423-5P
levels in plasma to identify patients with heart failure.
Our study showed thatmiR-423-5p levels are also positively
related to NT-proBNP levels in patients with DCM. Similarly,
Tijsen demonstrated a correlation between the plasma levels
of miR-423-5p and NT-proBNP.9 Consequently, circulating
levels of miR-423-5p may reflect the severity of DCM.
MiR-146a and miR-155 are immunity-associated miRNAs
that may contribute to the development of heart failure.18
Prior studies showed that miR-146a and miR-155 levels are
increased in the myocardium of heart failure patients.4,19
Corsten showed that inflammation-miRNA-155 plays
a central role in the induction of cardiac inflammation and
failure.20 Our study showed no dysregulation in the plasma
levels of miR-146a and miR-155 in patients with DCM. We
suspect that these two miRNAs are sufficiently localized that
any variation in myocardial levels is not detectable in plasma.
There are several limitations to this study. Although our
cohort of participants is relatively large when compared with
previous miRNAs studies, one of the major limitations of this
study is sample size. Secondly, we have not completed long-
term follow-ups of patients. Consequently, the potential
for miR-423-5p to be served as prognostic indicator for DCM
needs to be studied.
In conclusion, our results suggest that patientswith dilated
cardiomyopathyhave elevated plasma levels ofmiR-423-5p. In
addition, plasma concentration of miR-423-5p may reflect the
severity of DCM. The potential for miR-423-5P to discriminate
between heart failure caused by DCM patients and healthy
people warrants further investigation in larger populations.
Plasma levels of immunity-associatedmiR-146a, -155, and -126
were not significantly different between DCM and healthy
groups.
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